Medical news
-
A WFH Advisory on Particulate Matter in Emicizumab (HEMLIBRA) and Other Biologic Agents
Since the development of intravenous therapies, the presence of particulate matter in injectable drugs has been a concern for clinicians. While some particles can come...
-
WFH has spearheaded a scientific study updating the prevalence of hemophilia to higher numbers than previously estimated
The World Federation of Hemophilia (WFH) has spearheaded a scientific study updating the prevalence of hemophilia to higher numbers than previously estimated and providing, for...
-
Hurry! Earn CME credits with the gene therapy clinical education program
Enhance your knowledge of emerging gene therapy in hemophilia and claim up to 1.75 AMA PRA Category 1 Credits™ in 2019 with Clinical Advances in...
-
Recommendation on the use of Cryoprecipitate
The Medical Advisory Board of the WFH has published recommendation on the use of Cryoprecipitate for Treatment of Congenital Bleeding Disorders, on 26 April 2019. The recommendations are as follows:...
-
1st WBDR Data Report to be released soon
The WFH is proud to announce that the 1st World Bleeding Disorders Registry (WBDR) Data Report will be published this summer. The WBDR Data Report...
-
Novo Nordisk announces FDA approves the Biologics License Application for ESPEROCT®
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
-
WFH publication explores challenges and opportunities of gene therapy
In the first of a series of round table meetings, the World Federation of Hemophilia (WFH) Gene Therapy Round Table was convened in April 2018...
-
WFH supports MASAC’s recommendation on the risks of gene therapy trials for hemophilia
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
-
Now available: report on the Annual Global Survey 2017
The Report on the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) 2017 is now available in print and online at www.wfh.org/globalsurvey. The report includes...
